NeuroPace

NeuroPace
Name	NeuroPace
Type	Private
Industry	Medical devices
Founded	1997
Founder	Flavio B. Gil; Ramya Balakrishnan; M. Paul Schuelein
Headquarters	Mountain View, California
Area served	Worldwide
Products	Responsive Neurostimulation System

NeuroPace is a medical device company developing implantable neurostimulation systems for neurological disorders. Founded in the late 1990s, the company focuses on closed-loop neurostimulation and neuromodulation technologies for refractory focal epilepsy and related conditions. It operates in the medical device and biotechnology sectors and interacts with hospitals, academic centers, and regulatory agencies.

Company history

NeuroPace was founded in 1997 in Mountain View, California during a period of intense activity in Silicon Valley among startups such as Google, Tesla, Inc., and Cisco Systems. Early leadership included founders with backgrounds linked to research institutions like Stanford University and companies such as Medtronic and Boston Scientific. The company grew through venture funding rounds involving investors familiar from Sequoia Capital, Kleiner Perkins, and other Silicon Valley venture firms, and established collaborations with academic centers including Massachusetts General Hospital, Cleveland Clinic, and Johns Hopkins Hospital. Over time NeuroPace navigated competitive landscapes shaped by companies like Abbott Laboratories and regulatory environments influenced by the U.S. Food and Drug Administration and European regulators such as European Medicines Agency stakeholders.

Products and technology

NeuroPace's flagship product is an implantable responsive neurostimulation system combining sensing, signal processing, and stimulation delivery. The system integrates technologies from research fields represented by Stanford University School of Medicine, MIT Media Lab, and institutions such as Harvard Medical School for algorithms, and borrows engineering approaches akin to those used by Intel Corporation and Qualcomm for low-power electronics. Device components resemble implantable pulse generators manufactured by firms like Medtronic and Boston Scientific, and software planning tools align with platforms used by neuroscience groups at University of California, San Francisco and Université de Montréal. The company has developed closed-loop architectures inspired by work at University College London and Beth Israel Deaconess Medical Center, incorporating EEG sensing and responsive stimulation with implantable leads comparable to technologies from St. Jude Medical.

Clinical applications and indications

The primary indication for NeuroPace's system is treatment-resistant focal epilepsy evaluated at tertiary epilepsy centers such as Mayo Clinic, Cleveland Clinic, and Mount Sinai Health System. The device is used by neurologists and neurosurgeons affiliated with programs at Massachusetts General Hospital and Johns Hopkins Hospital for patients not amenable to resective surgery performed at centers like Brigham and Women's Hospital. Research collaborations extend to pediatric and adult epilepsy programs at Great Ormond Street Hospital and Children's Hospital of Philadelphia. Off-label and investigational uses have been explored in conditions studied at institutions including UCLA Health and Columbia University Irving Medical Center, with interest from specialists influenced by findings from groups at University of Pennsylvania and Northwestern Medicine.

Regulatory approvals and safety

NeuroPace obtained regulatory clearance following trials and submissions to agencies such as the U.S. Food and Drug Administration and notified bodies within the European Union. The company navigated pathways similar to other device makers like Medtronic and Abbott Laboratories to gain market access. Safety monitoring and post-market surveillance involve reporting systems coordinated with hospitals including Cleveland Clinic and Mayo Clinic and device registry efforts analogous to those coordinated by American Academy of Neurology and International League Against Epilepsy. The device safety profile has been discussed at conferences hosted by American Epilepsy Society and in regulatory briefings with agencies like the FDA and European counterparts.

Clinical trials and evidence

Pivotal clinical studies assessing efficacy and safety were conducted at multiple academic centers such as Massachusetts General Hospital, University of California, San Francisco, Cleveland Clinic, and Johns Hopkins Hospital. Trial designs paralleled methodology used in neuromodulation trials from Medtronic and featured outcome measures commonly reported by groups at Yale School of Medicine and University of Pennsylvania Perelman School of Medicine. Results have been presented at meetings organized by American Epilepsy Society and published by authors affiliated with Harvard Medical School and Stanford University. Ongoing and investigator-initiated studies involve consortia including researchers from Columbia University, Duke University School of Medicine, and Icahn School of Medicine at Mount Sinai.

Business operations and partnerships

NeuroPace's commercial operations include relationships with hospitals, payers such as Centers for Medicare & Medicaid Services, and supply chain partners comparable to contracts held by Medtronic and Boston Scientific. Strategic partnerships and distribution agreements have been formed with international medical device distributors operating in regions served by companies like B. Braun and Stryker Corporation. Research and collaboration agreements have linked NeuroPace with academic centers including Stanford University, Massachusetts General Hospital, and Johns Hopkins University for clinical adoption, training, and technology development. Corporate governance and financing have involved venture capital and later investors similar to participants in rounds for companies like Genentech and Amgen.

Category:Medical device companies